Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in ...
Drug Store News11d
Samsung Bioepis, Teva ink deal for Soliris biosimilar
Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...
Nasdaq16d
Samsung Bioepis and Teva Pharmaceutical Enter Partnership for EPYSQLI® Biosimilar to Enhance Treatment Options for Rare Disease Patients in the U.S.
Marks a significant advancement in offering new treatment options for patients with rare diseases like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and ...
Business Insider16d
Samsung Bioepis, Teva Enter License, Development, Commercialization Agreement For EPYSQLI
(RTTNews) - Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis biosimilar to ...
WGNO16d
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies ...